Galectin Therapeutics reported $-6193000 in Equity Capital and Reserves for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Bristol Myers Squibb BMY:US $ 32600M 1020M
Galectin Therapeutics GALT:US $ -6.19M 8.81M
Gilead Sciences GILD:US $ 20215M 288M
Idera Pharmaceuticals IDRA:US $ 21.13M 4.71M
Intercept Pharmaceuticals ICPT:US $ -369.83M 1.93M
Regulus Therapeutics RGLS:US $ 49.24M 5.72M
Vital Therapies VTL:US $ 127.85M 10.11M
YTE INCY:US $ 4085.06M 221.99M